Cost-Effectiveness of Vemurafenib Vs Ipilimumab Plus Dacarbacine in the Treatment of Non-Resectable Metastasic Melanoma with Braf600e Mutation in Colombia.

Autor:	Rosselli, D1, Castañeda-Cardona, C2, Bayona, JG2, Díaz Toro, YR3, Saenz Ariza, SA3, Bayona, J G2 (AUTHOR), Díaz Toro, Y R3 (AUTHOR), Saenz Ariza, S A3 (AUTHOR)
Zdroj:	Value in Health. Nov2015, Vol. 18 Issue 7, pA822-A822. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect